Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

US10039753B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Karen Coffman · Pawcatuck, US
• Paul Galatsis · Newton, US
• Michelle Renee Garnsey · Medford, US
• Jaclyn Louise Henderson · Cambridge, US
• Bethany Lyn Kormos · Somerville, US
• Ravi G. Kurumbail · East Lyme, US
• Martin Youngjin Pettersson · Waterford, US
• Matthew Richard Reese · Mystic, US
• Antonia Friederike Stepan · Providence, US
• Patrick Robert Verhoest · Newton, US
• Travis T. Wager · Brookline, US

Key dates

• Filing date: Sep 12, 2016
• Grant date: Aug 7, 2018
• Expiry date: Sep 12, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.